Critical Needs in Advancing Shigella Vaccines for Global Health

Advancing new O-antigen-based Shigella vaccines is critically dependent on development of an international standard serum and harmonized ELISA, demonstration of field efficacy in young children in low- and middle-income countries, and early engagement with regulators and policy makers.

Detalles Bibliográficos
Autores principales: MacLennan, Calman A, Talaat, Kawsar R, Kaminski, Robert W, Cohen, Dani, Riddle, Mark S, Giersing, Birgitte K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Perspectives
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9071279/
https://www.ncbi.nlm.nih.gov/pubmed/34558631
http://dx.doi.org/10.1093/infdis/jiab462
_version_ 1784700818372427776
author MacLennan, Calman A
Talaat, Kawsar R
Kaminski, Robert W
Cohen, Dani
Riddle, Mark S
Giersing, Birgitte K
author_facet MacLennan, Calman A
Talaat, Kawsar R
Kaminski, Robert W
Cohen, Dani
Riddle, Mark S
Giersing, Birgitte K
author_sort MacLennan, Calman A
collection PubMed
description Advancing new O-antigen-based Shigella vaccines is critically dependent on development of an international standard serum and harmonized ELISA, demonstration of field efficacy in young children in low- and middle-income countries, and early engagement with regulators and policy makers.
format Online
Article
Text
id pubmed-9071279
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-90712792022-05-06 Critical Needs in Advancing Shigella Vaccines for Global Health MacLennan, Calman A Talaat, Kawsar R Kaminski, Robert W Cohen, Dani Riddle, Mark S Giersing, Birgitte K J Infect Dis Perspectives Advancing new O-antigen-based Shigella vaccines is critically dependent on development of an international standard serum and harmonized ELISA, demonstration of field efficacy in young children in low- and middle-income countries, and early engagement with regulators and policy makers. Oxford University Press 2021-09-24 /pmc/articles/PMC9071279/ /pubmed/34558631 http://dx.doi.org/10.1093/infdis/jiab462 Text en © The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Perspectives
MacLennan, Calman A
Talaat, Kawsar R
Kaminski, Robert W
Cohen, Dani
Riddle, Mark S
Giersing, Birgitte K
Critical Needs in Advancing Shigella Vaccines for Global Health
title Critical Needs in Advancing Shigella Vaccines for Global Health
title_full Critical Needs in Advancing Shigella Vaccines for Global Health
title_fullStr Critical Needs in Advancing Shigella Vaccines for Global Health
title_full_unstemmed Critical Needs in Advancing Shigella Vaccines for Global Health
title_short Critical Needs in Advancing Shigella Vaccines for Global Health
title_sort critical needs in advancing shigella vaccines for global health
topic Perspectives
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9071279/
https://www.ncbi.nlm.nih.gov/pubmed/34558631
http://dx.doi.org/10.1093/infdis/jiab462
work_keys_str_mv AT maclennancalmana criticalneedsinadvancingshigellavaccinesforglobalhealth
AT talaatkawsarr criticalneedsinadvancingshigellavaccinesforglobalhealth
AT kaminskirobertw criticalneedsinadvancingshigellavaccinesforglobalhealth
AT cohendani criticalneedsinadvancingshigellavaccinesforglobalhealth
AT riddlemarks criticalneedsinadvancingshigellavaccinesforglobalhealth
AT giersingbirgittek criticalneedsinadvancingshigellavaccinesforglobalhealth

Ejemplares similares